Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. (Q47809579)

5 February 2018

title

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. (English)

1 reference

5 February 2018

1 reference

1 reference

1 reference

D Mutimer

1

1 reference

5 February 2018

N Naoumov

2

1 reference

5 February 2018

P Honkoop

3

1 reference

5 February 2018

G Marinos

4

1 reference

5 February 2018

M Ahmed

5

1 reference

5 February 2018

R de Man

6

1 reference

5 February 2018

P McPhillips

7

1 reference

5 February 2018

M Johnson

8

1 reference

5 February 2018

R Williams

9

1 reference

5 February 2018

E Elias

10

1 reference

5 February 2018

S Schalm

11

1 reference

5 February 2018

publication date

1 June 1998

1 reference

5 February 2018

published in

Journal of Hepatology

1 reference

5 February 2018

volume

28

1 reference

5 February 2018

issue

6

1 reference

5 February 2018

page(s)

923-929

1 reference

5 February 2018

Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Repeated courses of alpha-interferon for treatment of chronic hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Pilot study of ribavirin and interferon-beta for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Therapy of chronic hepatitis B with a 6-month course of ribavirin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Pharmacokinetics of interferon alpha-2b in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980338-3

7 January 2021

10.1016/S0168-8278(98)80338-3

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

9672165

1 reference

5 February 2018